Demand for weight-loss drugs spurs Novo Nordisk to invest €2.1bn in French production site

Image: JHVEPhoto via AdobeStock - stock.adobe.com

Danish drug company Novo Nordisk is to invest 16 billion Danish kroner (€2.1 billion) to expand its production facilities in Chartres, France amid high demand for its weight-loss drugs Ozempic and Wegovy.

The investment involves significantly increasing the capacity of its manufacturing site and extending its current quality control laboratory.

The new multi-product facilities will more than double the footprint of the site.

Construction work is expected to employ around 2,000 people and will gradually be finalised from 2026 to 2028.

Henrik Wulff, executive vice president, product supply, quality & IT at Novo Nordisk said, “Our continued investments in our manufacturing sites across the globe demonstrate the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases.”